Nektar Therapeutics
NKTR
236 hedge funds and large institutions have $3.4B invested in Nektar Therapeutics in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 70 increasing their positions, 84 reducing their positions, and 34 closing their positions.
16% more capital invested
Capital invested by funds: $2.93B → $3.4B (+$463M)
8% more call options, than puts
Call options by funds: $9.18M | Put options by funds: $8.48M
2.85% less ownership
Funds ownership: 96.08% → 93.23% (-2.8%)
4% less funds holding
Funds holding: 246 → 236 (-10)
17% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 84
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$34.4M |
| 2 |
DFO
Duquesne Family Office
New York
|
+$20.7M |
| 3 |
BlackRock
New York
|
+$13.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.16M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$7.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.1M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$16.5M |
| 4 |
D.E. Shaw & Co
New York
|
-$11.9M |
| 5 |
Goldman Sachs
New York
|
-$11.8M |
NKTR Hedge Fund Activity: Q1 2021 in Review
236 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2021, worth a combined $3.4B — up 16% from $2.93B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of NKTR and 26 opened new positions — a net loss of 8 holders — while 84 trimmed existing stakes and 70 added.
The largest buyer was Ameriprise, adding an estimated $34.4M. The largest seller was Wellington Management Group, cutting an estimated $41.7M.
- 236 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2021, down from 246 in Q4 2020.
- Funds reported $3.4B of Nektar Therapeutics stock for Q1 2021, up 16% quarter-over-quarter.
- 26 funds opened new Nektar Therapeutics positions in Q1 2021 and 34 closed out, a net change of -8 holders.
- The largest Nektar Therapeutics buyer in Q1 2021 was Ameriprise, an estimated $34.4M added.
- The largest Nektar Therapeutics seller in Q1 2021 was Wellington Management Group, an estimated $41.7M sold.
Based on aggregated 13F filings for Q1 2021.